Further, addition of FGF-2 to breast cancer cell lines in vitro impairs the effects of non-steroidal AIs and tamoxifen whilst downregulation of FGFR1 by siRNAs sensitises breast cancer cells to these agents5. Here, FGF2 is linked to breast cancer.